Takeda inks academic alliance for obesity and schizophrenia research
This article was originally published in Scrip
Executive Summary
Takeda is continuing to pursue open innovation alliances to strengthen its R&D pipeline, this time linking up with Kyoto University in Japan to discover novel drugs acting on the CNS for the treatment of obesity and schizophrenia.